Literature DB >> 29415791

Association between increased serum interleukin-6 levels and sustained attention deficits in patients with major depressive disorder.

Gang Ye1, Guang Zhong Yin1, Zhen Tang1, Jia Lin Fu1, Jie Chen1, Shan Shan Chen2, Jia Li1, Tian Fu1, Xin Yu2, Dong Wu Xu2, Jeffrey K Yao3, Li Hui1.   

Abstract

BACKGROUND: The pathophysiology of cognitive impairment in patients with the major depressive disorder (MDD) may involve neuroinflammation mediated by cytokines.
OBJECTIVE: The aim of this study was to examine the serum interleukin-6 (IL-6) levels, sustained attention, and their association in patients with MDD.
METHODS: Thirty patients with MDD and 30 healthy controls were enrolled in this case-control study. Sustained attention was measured using the Rapid Visual Information Processing (RVP) task in the Cambridge Neuropsychological Tests Automated Battery. The serum IL-6 levels of all subjects were assessed by sandwich enzyme-linked immunosorbent assays.
RESULTS: There were significant differences in the log10RVP total hits, log10RVP total misses, and log10RVP mean latency between patients with MDD and healthy controls (F = 6.04, p = 0.017; F = 19.77, p < 0.0001; F = 14.42, p < 0.0001, respectively). The serum levels of Log10IL-6 were significantly higher in patients with MDD than in healthy controls (F = 192.27, p < 0.0001). The log10IL-6 levels were also positively correlated with the log10RVP mean latency in patients with MDD (r = 0.45, p = 0.013). A further stepwise multivariate regression analysis indicated that the log10IL-6 levels were significantly associated with the log10RVP mean latency in patients with MDD (β = 0.31, t = 2.41, p = 0.025).
CONCLUSIONS: Our data suggested that increased IL-6 levels were associated with the psychopathology of MDD, and that abnormal IL-6 levels were implicated in the impairment of sustained attention in patients with MDD.

Entities:  

Keywords:  Association; interleukin-6; major depressive disorder; sustained attention

Mesh:

Substances:

Year:  2018        PMID: 29415791     DOI: 10.1017/S0033291718000090

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  11 in total

1.  The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis.

Authors:  M Morrens; C Overloop; V Coppens; E Loots; M Van Den Noortgate; S Vandenameele; M Leboyer; L De Picker
Journal:  Mol Psychiatry       Date:  2022-04-28       Impact factor: 15.992

2.  Comparisons of Serum Interleukin-8 Levels in Major Depressive Patients With Drug-Free Versus SSRIs Versus Healthy Controls.

Authors:  Zhen Hua Zhu; Xiao Ying Song; Li Juan Man; Peng Chen; Zhen Tang; Rong Hua Li; Cai Fang Ji; Ning Bin Dai; Fang Liu; Jing Wang; Jianping Zhang; Qiu Fang Jia; Li Hui
Journal:  Front Psychiatry       Date:  2022-04-14       Impact factor: 4.157

Review 3.  An Integrative Approach to Neuroinflammation in Psychiatric disorders and Neuropathic Pain.

Authors:  Diana I Lurie
Journal:  J Exp Neurosci       Date:  2018-08-13

4.  Peripheral blood lymphocyte subpopulations in patients with bipolar disorder type II.

Authors:  Krzysztof Pietruczuk; Katarzyna A Lisowska; Karol Grabowski; Jerzy Landowski; Wiesław J Cubała; Jacek M Witkowski
Journal:  Sci Rep       Date:  2019-04-10       Impact factor: 4.379

5.  The Inter-Regional Connectivity Within the Default Mode Network During the Attentional Processes of Internal Focus and External Focus: An fMRI Study of Continuous Finger Force Feedback.

Authors:  Zhi-Wei Zhou; Xia-Qing Lan; Yan-Tong Fang; Yun Gong; Yu-Feng Zang; Hong Luo; Hang Zhang
Journal:  Front Psychol       Date:  2019-09-26

Review 6.  Neuroimmune Mechanisms as Novel Treatment Targets for Substance Use Disorders and Associated Comorbidities.

Authors:  Mark D Namba; Jonna M Leyrer-Jackson; Erin K Nagy; M Foster Olive; Janet L Neisewander
Journal:  Front Neurosci       Date:  2021-04-15       Impact factor: 4.677

Review 7.  Cognitive Impairment and Neurocognitive Profiles in Major Depression-A Clinical Perspective.

Authors:  Åsa Hammar; Eivind Haga Ronold; Guro Årdal Rekkedal
Journal:  Front Psychiatry       Date:  2022-03-08       Impact factor: 4.157

8.  Neurofilament Light Chain Is a Novel Biomarker for Major Depression and Related Executive Dysfunction.

Authors:  Mu-Hong Chen; Yu-Li Liu; Hsiang-Wei Kuo; Shih-Jen Tsai; Ju-Wei Hsu; Kai-Lin Huang; Pei-Chi Tu; Ya-Mei Bai
Journal:  Int J Neuropsychopharmacol       Date:  2022-02-11       Impact factor: 5.176

9.  Correlation between anxiety-depression symptoms and immune characteristics in inpatients with 2019 novel coronavirus in Wuhan, China.

Authors:  Congchong Wu; Zhiying Zhou; Li Ni; Jiang Cao; Meifang Tan; Xiu Wu; Yi Xu; Jianbo Hu
Journal:  J Psychiatr Res       Date:  2021-07-15       Impact factor: 4.791

Review 10.  Role of Interleukin-6 in Depressive Disorder.

Authors:  Emily Yi-Chih Ting; Albert C Yang; Shih-Jen Tsai
Journal:  Int J Mol Sci       Date:  2020-03-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.